FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980281337> ?p ?o ?g. }

• W2980281337 endingPage "S955" @default.
• W2980281337 startingPage "S955" @default.
• W2980281337 abstract "INTRODUCTION: Candida species are a part of normal GI flora however some patients, especially during immunocompromised state can develop Candida esophagitis (CE). Sorafenib is a tyrosine kinase inhibitor commonly used for treatment of renal cell and hepatocellular carcinoma (HCC). We report one of the most severe cases of CE following Sorafenib. CASE DESCRIPTION/METHODS: An 84-year-old man was admitted for a 2-week history of solid food dysphagia with nausea, chocking and regurgitation following food intake. His medical history included type 2 diabetes mellitus and stage IV (T3N0M1) metastatic HCC. Patient had been taking Sorafenib 400mg twice daily for the last 6 months and recently received palliative radiotherapy (RT) for a pathologic pelvic fracture due to bone metastasis. Patient denied any vomiting, odynophagia, anorexia, fever, chills, abdominal pain, diarrhea or constipation. On clinical examination, he had normal vital signs, appeared thin and cachectic, had oral thrush underneath artificial dentures while the rest of the clinical examination was unremarkable. His lab-work showed borderline leukocytosis of 11.9 10 3 /µL, mild anemia with Hb of 10.5 g/dl, and normal electrolytes, renal function and liver integrity enzymes. He underwent an esophagogastroduodenoscopy (EGD) which interestingly showed esophagus completely lined with thick whitish adherent plaques, diffuse atrophic gastropathy and normal duodenum. Despite the esophagus having no tortuosity, rings or strictures, it required considerable amount of force to advance the endoscope through the copious amount of exudate in the esophagus which would explain the patient’s dysphagia. We obtained biopsy and brushing from esophagus which revealed abundant inflammatory cells and fungal organisms consistent with Candida species. Patient was given a loading dose of 400 mg of Fluconazole followed by 200 mg daily for 21 days. After completion of therapy, patient’s symptoms had improved, and he was tolerating a regular diet. DISCUSSION: Upon literature review we found one case series of 2 patients mentioning CE as a side effect with the use of Sorafenib. Unlike above case series in which patients developed CE soon after initiation of Sorafenib, our patient developed symptoms after being on it for 6 months. Physicians should be aware when using Sorafenib that it can induce an immunosuppressive state with an increased risk of CE. Delayed diagnosis and subsequent treatment may affect the nutritional status and subsequently the overall survival in these patients." @default.
• W2980281337 created "2019-10-18" @default.
• W2980281337 creator A5003772707 @default.
• W2980281337 creator A5075280954 @default.
• W2980281337 creator A5085791776 @default.
• W2980281337 date "2019-10-01" @default.
• W2980281337 modified "2023-09-23" @default.
• W2980281337 title "1707 Sorafenib-Induced Severe Candida Esophagitis" @default.
• W2980281337 doi "https://doi.org/10.14309/01.ajg.0000596360.03919.53" @default.
• W2980281337 hasPublicationYear "2019" @default.
• W2980281337 type Work @default.
• W2980281337 sameAs 2980281337 @default.
• W2980281337 citedByCount "1" @default.
• W2980281337 countsByYear W29802813372020 @default.
• W2980281337 crossrefType "journal-article" @default.
• W2980281337 hasAuthorship W2980281337A5003772707 @default.
• W2980281337 hasAuthorship W2980281337A5075280954 @default.
• W2980281337 hasAuthorship W2980281337A5085791776 @default.
• W2980281337 hasConcept C126322002 @default.
• W2980281337 hasConcept C141071460 @default.
• W2980281337 hasConcept C2776980227 @default.
• W2980281337 hasConcept C2777819096 @default.
• W2980281337 hasConcept C2778451229 @default.
• W2980281337 hasConcept C2779134260 @default.
• W2980281337 hasConcept C2779920096 @default.
• W2980281337 hasConcept C2780852908 @default.
• W2980281337 hasConcept C2780955771 @default.
• W2980281337 hasConcept C2781143854 @default.
• W2980281337 hasConcept C43270747 @default.
• W2980281337 hasConcept C71924100 @default.
• W2980281337 hasConcept C90924648 @default.
• W2980281337 hasConceptScore W2980281337C126322002 @default.
• W2980281337 hasConceptScore W2980281337C141071460 @default.
• W2980281337 hasConceptScore W2980281337C2776980227 @default.
• W2980281337 hasConceptScore W2980281337C2777819096 @default.
• W2980281337 hasConceptScore W2980281337C2778451229 @default.
• W2980281337 hasConceptScore W2980281337C2779134260 @default.
• W2980281337 hasConceptScore W2980281337C2779920096 @default.
• W2980281337 hasConceptScore W2980281337C2780852908 @default.
• W2980281337 hasConceptScore W2980281337C2780955771 @default.
• W2980281337 hasConceptScore W2980281337C2781143854 @default.
• W2980281337 hasConceptScore W2980281337C43270747 @default.
• W2980281337 hasConceptScore W2980281337C71924100 @default.
• W2980281337 hasConceptScore W2980281337C90924648 @default.
• W2980281337 hasIssue "1" @default.
• W2980281337 hasLocation W29802813371 @default.
• W2980281337 hasOpenAccess W2980281337 @default.
• W2980281337 hasPrimaryLocation W29802813371 @default.
• W2980281337 hasRelatedWork W1999910549 @default.
• W2980281337 hasRelatedWork W2053036048 @default.
• W2980281337 hasRelatedWork W2056156526 @default.
• W2980281337 hasRelatedWork W207475135 @default.
• W2980281337 hasRelatedWork W2088683559 @default.
• W2980281337 hasRelatedWork W2200587925 @default.
• W2980281337 hasRelatedWork W2354144855 @default.
• W2980281337 hasRelatedWork W2945336718 @default.
• W2980281337 hasRelatedWork W3138367641 @default.
• W2980281337 hasRelatedWork W4255361753 @default.
• W2980281337 hasVolume "114" @default.
• W2980281337 isParatext "false" @default.
• W2980281337 isRetracted "false" @default.
• W2980281337 magId "2980281337" @default.
• W2980281337 workType "article" @default.